.png){kind=icon}
.png){kind=icon}
Return
Faricimab for Polypoidal Choroidal Vasculopathy: 48-Week Results from the Phase 3b/4 SALWEEN Trial
.png){kind=icon}
OA
AI
C
W
S
T
J
X
P
A
Y
R
A
P
T
DOI：10.1016/j.oret.2026.08.003.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
To evaluate the 48-week efficacy and safety results for faricimab in patients with polypoidal choroidal vasculopathy (PCV).
Keywords:
Angiopoietin-2
faricimab
polypoidal choroidal vasculopathy
treat-and-extend
vascular endothelial growth factor
AE
adverse event
ANG-2
angiopoietin-2
BCVA
best-corrected visual acuity
CI
confidence interval
CST
central subfield thickness
ETDRS
Early Treatment Diabetic Retinopathy Study
ICGA
indocyanine green angiography
IOI
intraocular inflammation
IRF
intraretinal fluid
nAMD
neovascular age-related macular degeneration
PCV
polypoidal choroidal vasculopathy
QXW
every X weeks
RCT
randomized controlled trial
RPE
retinal pigment epithelium
SAE
serious adverse event
SD
standard deviation
SD-OCT
spectral-domain optical coherence tomography
SRF
subretinal fluid
T&E
treat-and-extend
VEGF
vascular endothelial growth factor
VPDT
verteporfin photodynamic therapy
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
5.7
Papers:
584
Citations:
4.1K
Organization
Cited Papers